scholarly journals Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Carmen P. Escalante ◽  
Ali Zalpour
Keyword(s):  
Primary Care ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Drug Class ◽  
Primary Care Providers ◽  
The United States ◽  
Vascular Endothelial ◽  
Care Providers ◽  
Vegf Inhibitors ◽  
Endothelial Growth Factor

Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced by vascular endothelial growth factor (VEGF) inhibitors. It is imperative that these healthcare providers are aware of basic aspects of this drug class, as its use has increased significantly in the last several years. Uncontrolled or malignant hypertension due to these agents should be recognized readily and treated early to prevent more severe outcomes. This overview provides a brief background on the role of VEGF and angiogenesis in tumor metabolism as well as theories of the mechanism of VEGF inhibitors and hypertension. Helpful clinical practice aspects including the types of inhibitors used in the United States and their pharmacologic characteristics will be discussed. Also, diagnosis and treatment of hypertension induced by vascular endothelial growth factors are reviewed. A summary of key aspects of this drug class and hypertension is included.

scholarly journals The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration

2018 ◽  
Vol 19 (9) ◽  
pp. 2611 ◽  
Author(s):  
Kelvin Teo ◽  
Mark Gillies ◽  
Samantha Fraser-Bell
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Vegf Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations as compared to Caucasians. PCV and nAMD share pathological mechanisms, including pathological expression of vascular endothelial growth factor (VEGF). The advent of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be considered. This review aims to summarize the current evidence for the treatment of PCV, especially whether VEGF inhibitors should be used alone or in combination with PDT.

scholarly journals The recent advances in Vascular endothelial growth factor and metabolic syndrome in prostate cancer

2021 ◽  
Vol 5 (1) ◽  
pp. 13-18
Author(s):  
Ya-nan Zhou ◽  
Jin-qi Song ◽  
Gang-liang Tu ◽  
Hui Xu ◽  
Meng Ding
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metabolic Syndrome ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
The United States ◽  
Epidemiological Studies ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Diet And Lifestyle

Prostate cancer is one of the most common male malignant tumors in Western countries. In the United States, there are about 170,000 new cases of prostate cancer in 2019, ranking second only to lung cancer.1, 2 In recent years, the incidence of prostate cancer in China is gradually increasing occupying the third place among male urogenital malignancies. The metastasis of prostate cancer mainly depends on blood vessels and lymphatic vessels, and the late discovery and poor prognosis of patients are the main reasons for the high fatality rate.2 Relevant epidemiological studies on immigration have found that the incidence of PCa in The Asian population in the United States is as high as 77.8 / l0000, which is similar to local residents and significantly higher than that in the native population in Asia. This suggests that, in addition to race and family history, different diet and lifestyle in China and the West may play an important role in the development and progression of PCa.3 Epidemiological studies have shown an association between geographic location and prostate cancer risk. In fact, the incidence of prostate cancer in Western men is 15 times higher than in Asian men. This suggests that environmental factors or lifestyle, especially diet and nutrition, may play a key role in the occurrence and development of prostate cancer.4 To some extent, metabolic syndrome reflects the diet and lifestyle of patients and is closely related to the occurrence and development of prostate cancer. In addition, Vascular endothelial growth factor (VEGF) as a kind of multi functional cytokine works through specific role in endothelial cells.It can promote endothelial cell proliferation, migration, and increase Vascular permeability. And VEGF can be induced in the body for blood vessel growth, angiogenesis, is closely related to tumorigenesis and metastasis. Numerous recent studies have shown that VEGF is closely related to the occurrence and development of prostate cancer and metabolic syndrome.5 In this paper, multiple physiological and pathological mechanisms of VEGF and metabolic syndrome associated with prostate cancer are reviewed. 

Predictive value of changes in plasma vascular endothelial growth factor at eight weeks after lenvatinib administration in patients with unresectable hepatocellular carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4594-4594
Author(s):  
Kaoru Tsuchiya ◽  
Masayuki Kurosaki ◽  
Shun Kaneko ◽  
Yutaka Yasui ◽  
Sakura Kirino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Overall Survival ◽  
Growth Factor ◽  
Objective Response ◽  
Plasma Concentrations ◽  
Vascular Endothelial ◽  
Vegf Inhibitors ◽  
Unresectable Hepatocellular Carcinoma ◽  
Endothelial Growth Factor

4594 Background: Lenvatinib (LEN) has been used in patients with unresectable hepatocellular carcinoma (u-HCC) and there is no established predictive biomarker. Previously it was reported that a plasma vascular endothelial growth factor (VEGF) concentration decrease at 8 weeks after starting sorafenib might predict favorable overall survival (OS) in patients with u-HCC (Tsuchiya, et al. Cancer, 2013). We aimed to investigate the value of changes in plasma VEGF at 8 weeks after LEN administration in patients with u-HCC. Methods: Forty-six patients with u-HCC who received LEN between April 2018 and August 2019 at our institution were enrolled. Plasma concentrations of VEGF and serum α-fetoprotein (AFP) levels were measured at baseline, 4 and 8 weeks after administration of LEN. A VEGF decrease was defined as > 5% decrease during 8 weeks after the beginning of LEN therapy. AFP response was defined as > 20% decrease during 8 weeks according to the previous reports. Results: Median overall survival (OS) was not reached and progression-free survival (PFS) was 5.9 months. Median observation period and treatment duration were 10.1 and 6.3 months. The objective response rate and disease control rate by mRECIST criteria were 43.5% and 82.6%. Median PFS in patients who had a VEGF decrease at week 8 (n = 29) was significantly longer than those who did not have a VEGF decrease (n = 17; 7.1 months vs 5.0 months; p = 0.014). AFP response was not associated with PFS. There were no significant differences in baseline VEGF, AFP, ALBI score, and extrahepatic metastasis between the patients with and without a VEGF decrease. A VEGF decrease was significantly associated with radiological objective response (p = 0.001) and 18 of 20 patients who achieved CR (n = 3) or PR (n = 17) had a VEGF response in LEN therapy. Conclusions: A decrease of plasma VEGF level at 8 weeks in patients with u-HCC on LEN was significantly associated with PFS. Changes in plasma VEGF could become a new biomarker for molecular targeted therapies including VEGF inhibitors in patients with unresectable HCC.

Sign in / Sign up

Export Citation Format

Share Document